| Name | Title | Contact Details |
|---|
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and com...
Chromatin is unlocking the potential of plants to produce greater value and meaningful products for consumers, growers, seed producers, and processors. At the same time, the company's technology can benefit the environment through decreased use of pesticides and fertilizers. The company's mini-chromosome technology simultaneously introduces multiple genetic traits into plants, reducing the time and cost required to develop improved and novel crop-based products, such as medicines, biomaterials, textiles and nutritionally improved foods. These products are enabled while allowing growers to enjoy the benefits of the most up-to-date agronomic traits, such as herbicide tolerance, pest resistance, and diseases resistance. Mini-chromosomes also provide unprecedented precision and control of new traits at every point in a plant's life cycle, from seed to field and beyond. Crop stewardship is at the core of Chromatin's values, and the company is equally focused on using its technology to introduce sustainable, healthy agricultural practices while enhancing commercial value and quality of life.
Criada em 1977, são mais de quatro décadas de uma história construída com qualidade, acessibilidade e inovação, sempre com o foco no bem-estar da população brasileira. Sobre a Cimed: Somos uma das maiores farmacêuticas do país. Com mais de 40 anos de história, uma das poucas empresas do setor que permanece totalmente brasileira e independente até hoje. São mais de 600 produtos no catálogo e uma distribuição nacional para mais de 60 mil pontos de vendas. Além disso, a Cimed é líder em todos os setores em que atua. Temos nosso complexo fabril em Pouso Alegre (MG), o centro de distribuição central e a gráfica em São Sebastião da Bela Vista (MG), além de contar com 25 centros de distribuição espalhados pelo país. Com sede administrativa em São Paulo, são cerca de 5 mil colaboradores em todo Brasil. Somos, também, apoiadores do esporte nacional, patrocinando a Confederação Brasileira de Futebol. Projeto +: Mais de 280 mil m², esse é o tamanho do terreno da nova fábrica de sólidos orais da Cimed em Pouso Alegre, no Sul de Minas Gerais, a ser finalizada até 2022. A nova unidade terá aproximadamente 44 mil m² de área construída, fazendo com que a capacidade produtiva da área de sólidos passe de 28 milhões para 40 milhões comprimidos por mês, podendo chegar a 60 milhões. Pesquisa e Desenvolvimento: A Cimed é uma das poucas empresas do setor a ter o seu próprio centro de bioequivalência e a única a realizar todas as etapas de estudo necessárias para o registro de medicamentos genéricos e similares (clínica, analítica e estatística). Tudo isso é feito no Instituto Claudia Marques de Pesquisa e Desenvolvimento (ICM P&D), criado em 2004. Nossos números - Mais de 5 mil colaboradores - Mais de 60 mil pontos de venda - Presentes em mais de 90% das farmácias brasileiras - Cerca de 600 produtos no portfólio
PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our elastin-like polypeptide technology, which also serves as the engine for our preclinical pipeline. Our proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which may lead to less-frequent dosing and better patient compliance. PB1046 is a vasoactive intestinal peptide (VIP) receptor agonist that leverages our ELP technology for once-weekly dosing. PB1046 is being evaluated in clinical studies in pulmonary arterial hypertension (PAH) and in preclinical studies for the treatment of cardiomyopathy associated with dystrophinopathies. PhaseBio recently concluded a Phase 2a trial of PB1046 in patients with heart failure with reduced ejection fraction. We are also evaluating our development candidate PB2452, a reversal agent for the antiplatelet therapy ticagrelor, in clinical trials. PB2452 was exclusively licensed from MedImmune, the global biologics research and development arm of AstraZeneca, for global development and commercialization by PhaseBio. PhaseBio continues to explore opportunities to apply our ELP biopolymer technology to compounds that may benefit from its unique properties. We are privately owned, with headquarters and research laboratories in Malvern, PA.
Biolife Plasma Services is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.